Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 17/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | FLT3 | P36888 | 3/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL391746 | 0.90 | GPR119 (0.76) | GPR119CYP2C9KCNH2 | |
| SCHEMBL4721651 | 0.85 | GPR119 (0.60) | GPR119CYP2C9KCNH2FLT3CDK2 | |
| SCHEMBL13685341 | 0.80 | GPR119 (0.53) | GPR119CYP2C9KCNH2FLT3CDK2 | |
| SCHEMBL386785 | 0.80 | GPR119 (0.80) | GPR119CYP2C9KCNH2 | |
| SCHEMBL388233 | 0.79 | GPR119 (0.72) | GPR119CYP2C9KCNH2 | |
| SCHEMBL390295 | 0.79 | GPR119 (0.77) | GPR119CYP2C9KCNH2 | |
| SCHEMBL14823308 | 0.76 | GPR119 (0.73) | GPR119CYP2C9KCNH2 | |
| SCHEMBL389617 | 0.76 | GPR119 (0.73) | GPR119CYP2C9KCNH2 | |
| SCHEMBL12241594 | 0.75 | GPR119 (0.85) | GPR119CYP2C9KCNH2 | |
| SCHEMBL390253 | 0.75 | GPR119 (0.60) | GPR119CYP2C9KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1756084-A2 | SUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2007-02-28 | — | — | EP | claimed |
| WO-2005121121-A2 | SUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2005-12-22 | — | — | WO | claimed |
| CN-101420941-A | Use of GPR119 receptor agonists for increasing bone mass and for treating osteoporosis, and related combination therapies | ARENA PHARM INC (US) | 2009-04-29 | — | — | CN | disclosed |